Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Powell MA, et al. Among authors: gold ma. Gynecol Oncol. 2025 Jan;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. Epub 2024 Nov 12. Gynecol Oncol. 2025. PMID: 39531903 Clinical Trial.
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. Mirza MR, et al. Among authors: gold ma. Future Oncol. 2025 Jan;21(2):151-168. doi: 10.2217/fon-2023-0940. Epub 2024 Jul 11. Future Oncol. 2025. PMID: 38990090 Free PMC article.
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR. Powell MA, et al. Among authors: gold ma. Ann Oncol. 2024 Aug;35(8):728-738. doi: 10.1016/j.annonc.2024.05.546. Epub 2024 Jun 10. Ann Oncol. 2024. PMID: 38866180 Free article. Clinical Trial.
248 results